Todos os estudos
RecrutamentoExploratório terapêutico (Fase II)Intervencionista

C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA

Primary immune thrombocytopenia (ITP) is a blood condition that causes low levels of platelets, which are cells that help your blood clot. People with ITP often bruise easily or bleed more than usual. This Phase 2 study is testing an experimental medicine called PF-06835375. Researchers want to find out if this new injection can safely increase platelet counts in adults with moderate to severe ITP. Because this is an 'open-label' study, all participants will receive the study medicine at one of several planned doses—there is no dummy drug (placebo). Participants will also be given an allergy medicine (diphenhydramine) before their treatment to help prevent common injection reactions. Doctors will monitor participants closely over 12 to 16 weeks and beyond, checking their blood counts and watching for any side effects to see how well the treatment works.

Em resumo

Status
Recrutamento
Fase
Exploratório terapêutico (Fase II)
Patrocinador
Pfizer Inc.
Meta de inscrição
69
Iniciar
03 Jun 2024

Sobre o que é este estudo?

Primary immune thrombocytopenia (ITP) is an autoimmune condition. In a healthy body, blood cells called platelets stick together to stop bleeding when you get a cut or bruise. If you have ITP, your immune system mistakenly attacks and destroys your own platelets. This leaves you with a low platelet count, which can lead to easy bruising, purple spots on the skin, nosebleeds, or more serious bleeding problems.

While there are existing treatments for ITP, they do not work for everyone, and some can cause difficult side effects. This clinical trial is testing a new injectable drug known as PF-06835375. Scientists have designed this medicine to calm the immune system's attack on platelets, aiming to let platelet numbers return to safer levels.

This study is a Phase 2 trial, which means researchers are working out how well the medicine works and finding the right dose. Participants will receive one of several dose amounts. Doctors will follow participants for several months, testing blood samples to see if their platelet counts rise and staying watchful for any unwanted side effects. Finding new and better ways to treat ITP could help people manage their condition with fewer bleeding risks.

Pontos principais

  • Tests a new injection (PF-06835375) designed to raise platelet counts in adults with ITP.
  • Open to adults aged 18 and older with moderate to severe primary ITP.
  • All participants receive the study drug; there is no dummy treatment (placebo).
  • Requires regular clinic visits for blood tests, injections, and safety checks over several months.
  • Participation is completely voluntary and you can leave the study at any time.

Quem pode ser elegível?

This study is open to adults aged 18 and older of any sex who have been diagnosed with moderate to severe primary immune thrombocytopenia (ITP). It is meant for people whose platelet counts remain low and who may need new treatment options.

To join, participants must be able to attend regular clinic appointments for injections, health checks, and blood tests.

Not everyone will be able to take part. People with certain other underlying medical conditions, active infections, or those taking specific medications that could clash with the study drug may not be eligible. The study doctor will review your full medical history and run tests to decide if the trial is safe for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Are you aged 18 or older?
  2. Have you been diagnosed with primary immune thrombocytopenia (ITP)?
  3. Is your ITP currently considered moderate to severe?
  4. Are you willing to receive injections and have regular blood tests?
  5. Can you travel to a study centre for scheduled check-ups over several months?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you take part, you will visit a specialist hospital clinic regularly. During your visits, doctors and nurses will check your overall health, measure your vital signs, and take routine blood samples to monitor your platelet counts and immune cells. You will receive the study medicine as an injection. Before the injection, you may receive an antihistamine called diphenhydramine to help stop any mild allergic or infusion reactions. The main treatment phase lasts around 12 to 16 weeks, depending on the dose group you are in. After this, there will be follow-up checks so the medical team can see how you are doing over time.

Riscos e benefícios potenciais

Taking part may help increase your platelet counts and lower your risk of bleeding, although this cannot be guaranteed. You will also receive very close medical care and monitoring from a team of blood specialists. However, there are potential risks. Because PF-06835375 is an experimental medicine, it may cause unforeseen side effects or allergic reactions. The allergy medicine given beforehand can also cause mild sleepiness or dry mouth. Regular blood tests may cause brief discomfort or bruising. Taking part is completely voluntary, and you can change your mind and leave the study at any time without it affecting your standard NHS care.

Localizações (3)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Polônia
  • —
    Não verificado
    Chéquia
  • —
    Não verificado
    Hungria

Perguntas frequentes

What is primary immune thrombocytopenia (ITP)?

ITP is a blood disorder where your immune system mistakenly destroys your platelets, making it harder for your blood to clot and increasing the risk of bruising and bleeding.

Will I receive a placebo (dummy medicine)?

No. This is an 'open-label' study, which means every participant receives the real study medicine, and both you and your doctor will know the dose you are getting.

Why is diphenhydramine given before the injection?

Diphenhydramine is a common antihistamine medicine. It is given to help prevent mild allergic symptoms or reactions that can sometimes happen when receiving an injection of a new medicine.

Quanto tempo estarei no estudo?

The main part of the study lasts between 12 and 16 weeks, followed by further monitoring visits to check on your long-term health and platelet counts.

What happens if I want to stop taking part?

You can leave the trial at any time for any reason. Your regular doctors will support your decision and continue to provide standard treatment for your condition.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENT…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.